William Blair analyst Matt Phipps has reiterated their bullish stance on AMGN stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Matt Phipps has given his Buy rating due to a combination of factors, primarily driven by Amgen’s strong financial performance in the third quarter of 2025. The company reported revenues of $9.6 billion, surpassing both the firm’s and market consensus estimates of $9.0 billion. This robust performance led to an upward revision in the full-year revenue and earnings per share guidance, indicating positive momentum for the company.
Additionally, Phipps highlights the potential for further growth through Amgen’s diverse product portfolio, including promising assets like Repatha, Evenity, and Imdelltra. Despite some concerns regarding the MariTide trial’s focus and design, the analyst remains optimistic about the company’s future clinical and commercial success. The anticipation of Phase III results and the differentiated profile of MariTide in early 2027 further supports the Buy rating, suggesting continued upside potential for Amgen’s stock.
Phipps covers the Healthcare sector, focusing on stocks such as Merus, Upstream Bio, Inc., and Bristol-Myers Squibb. According to TipRanks, Phipps has an average return of 2.0% and a 44.98% success rate on recommended stocks.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $389.00 price target.